SEARCH

SEARCH BY CITATION

References

  • 1
    Adcock DM Sample integrity and preanalytical variables. In: Quality in Laboratory Hemostasis and Thrombosis. Kitchen S, Olson JD, Preston FE. (eds). Chichester, UK: Wiley-Blackwell; 2009: 3142.
  • 2
    Bolton-Maggs PHB, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004;10:593628.
  • 3
    CLSI. Collection, Transport and Processing of Blood Specimens for Testing Plasma-based coagulation assays and Molecular Haemostasis assays: Approved Guideline-5th edition. 2008:H21A5.
  • 4
    Lippi G, Blanckaert N, Bonini P, Green S, Kitchen S, Palicka V, Vassault AJ, Plebani M. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008;46:76472.
  • 5
    Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999;45:94256.
  • 6
    Marks V. False-positive immunoassay results: a multicentre survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem 2002;48:200816.
  • 7
    CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline – 3rd edition. Clinical and Laboratory Standards Institute: document. 2008; C28A3.
  • 8
    World Federation of Haemophilia. Diagnosis of haemophilia and other bleeding disorders: A Laboratory manual. Kitchen S, Mcgraw A, Enchenagucia M. (eds). www.wfh.org; 2010.
  • 9
    Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
  • 10
    Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987;70:16572.
  • 11
    Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992;80:19982005.
  • 12
    Keeling DM, Mackie IJ, Moody A, Watson HG, On behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The diagnosis of deep vein thrombosis in symptomatic outpatients and the potential for clinical assessment and D–dimer assays to reduce the need for diagnostic imaging. Br J Haematol 2004;124:1525.
  • 13
    Finney DJ. Statistical Method in Biological Assay, 3rd edn. London: Charles Griffin & Co. Ltd; 1978.
  • 14
    Curtis AD. The statistical evaluation of factor VIII clotting assays. Scand J Haematol 1984;33(Suppl. 41):5568.
  • 15
    Kirkwood TBL, Snape TJ. Biometric principles in clotting and clot lysis assays. Clin Lab Haematol 1980;2:15567.
  • 16
    Williams KN, Davidson JM, Ingram GI. A computer program for the analysis of parallel-line bioassays of clotting factors. Br J Haematol 1975;31:1323.
  • 17
    Lattes S, Appert-Flory A, Fischer F, Jambou D, Toulon P. Measurement of factor VIII activity using one stage assay: a calibration curve has not to systematically included in each run. Haemophilia 2011;17:13942.
  • 18
    NCCLS. Determination of Factor Coagulant Activities: Approved Guideline. 1997; H48A.
  • 19
    Gallimore MJ, Friberger P. Chromogenic peptide substrate assays and their clinical applications. Blood Rev, 1991;5:11727.
  • 20
    Mackie IJ, Gallimore M, Machin SJ. Contact factor proteases and the complexes formed with alpha-2-macroglobulin can interfere in protein C assays by cleaving amidolytic substrates. Blood Coagul Fibrinolysis 1992;3:58995.
  • 21
    Saah AJ, Hoover DR. “Sensitivity” and “specificity” reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med 1997;126:914.
  • 22
    Medicines and Healthcare Products Regulatory Agency (MHRA). Guidance Note 19 - Guidance Notes on In Vitro Diagnostic Medical Devices Directive 98/79/EC. www.mhra.gov.uk/Publications/Regulatoryguidance/Devices/Guidance.
  • 23
    Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med 1992;116:83740.
  • 24
    Brancaccio V, Ames PR, Glynn J, Iannaccone L, Mackie IJ. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul Fibrinolysis 1997;8:15560.
  • 25
    Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Haemostasis 1995;25:98105.
  • 26
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001;86:14359.
  • 27
    Marsh NA. Diagnostic uses of snake venom. Haemostasis 2001;31:2117.
  • 28
    Marsh N, Williams V. Practical applications of snake venom toxins in haemostasis. Toxicon 2005;45:117181.
  • 29
    Girolami A, Scapin M, Scarparo P, Vettore S. Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency. Am J Hematol 2008;83:8845.
  • 30
    Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol 1984;33(Suppl. 41):1324.
  • 31
    Erskine JG, Walker ID, Davidson JF. Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X. Clin Lab Haematol 1982;4:17986.
  • 32
    Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997;98:88792.
  • 33
    Rosborough TK, Jacobsen JM, Shepherd MF. Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients. Blood Coagul Fibrinolysis 2010;21:2424.
  • 34
    Barrowcliffe TW. Comparisons of one-stage and two-stage assays of Factor VIII:C. Scand J Haematol 1984;33(Suppl. 41):3954.
  • 35
    Cid AR, Calabuig M, Cortina V, Casana P, Haya S, Moret A, Cabrera N, Aznar JA. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008;14:104954.
  • 36
    Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954–>Leu substitution in the factor VIII A3 domain. Br J Haematol 1999;105:11236.
  • 37
    Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between one stage and 2 stage factor VIII assay methods in a subgroup of patients with haemophilia A. Br J Haematol 1994;87:8468.
  • 38
    Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 2006;136:13845.
  • 39
    Kitchen S, Hayward C, Negrier C, Dargaud Y. New developments in laboratory diagnosis and monitoring. Haemophilia 2010;16(Suppl. 5):616.
  • 40
    Rodgers SE, Duncan EM, Sobieraj-Teague M, Lloyd JV. Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Hematol 2009;31:1808.
  • 41
    Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346-Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A? Haemophilia 2008;14:7880.
  • 42
    Mumford AD, Laffan M, O'Donnell J, McVey JH, Johnson DJG, Manning RA, Kemball-Cook G. A Tyr346-Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002;118:58994.
  • 43
    Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002;28:24756.
  • 44
    Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000;84:9428.
  • 45
    Jennings I, Kitchen S, Woods TA, Preston FE. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003;1:26038.
  • 46
    Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009;35:42638.
  • 47
    Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII - an under diagnosed deficiency - are we using the right assays? J Thromb Haemost 2010;8:247882.
  • 48
    Oertel K, Hunfeld A, Specker E, Reiff C, Seitz R, Pasternack R, Dodt J. A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma. Anal Biochem 2007;367:1528.
  • 49
    Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:20920.
  • 50
    Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, Andrew M, Hirsh J, Ginsberg JS. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993;69:2315.
  • 51
    Tran Tri H, Duckert F. Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res 1985;40:5716.
  • 52
    Kottke-Marchant K, Duncan A. Antithrombin deficiency. Arch Pathol Lab Med 2002;126:132636.
  • 53
    Walker ID, Greaves M, Preston FE. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:51228.
  • 54
    Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blomback M. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 1992;99:22712.
  • 55
    Harper PL, Daly M, Price J, Edgar PF, Carrell RW. Screening for heparin binding variants of antithrombin. J Clin Pathol 1991;44:4779.
  • 56
    Kristensen SR, Rasmussen B, Pedersen S, Bathum L. Detecting antithrombin deficiency may be a difficult task–more than one test is necessary. J Thromb Haemost 2007;5:6178.
  • 57
    Rossi E, Chiusolo P, Za T, Marietti S, Ciminello A, Leone G, De Stefano V. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. Thromb Haemost 2007;98:6957.
  • 58
    Stocker K, Fischer H, Meier J, Brogli M, Svendsed L. Protein C activators in snake venoms. Behring Inst Mitt 1986;79:3747.
  • 59
    Cooper PC, Siddiq S, Morse C, Nightingale J, Mumford AD. Marked discrepancy between coagulometric Protein C activity assays with the pro-thrombotic Protein C Asn2Ile substitution. Int J Lab Hematol 2011;33:4516.
  • 60
    D'Angelo SV, Gilardoni F, D'Angelo A. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. Thromb Haemost 1989;62:8617.
  • 61
    de Moerloose P, Reber G, Bouvier CA. Spuriously low levels of protein C with a Protac activation clotting assay. Thromb Haemost 1988;59:543.
  • 62
    Jennings I, Kitchen S, Cooper PC, Rimmer JE, Woods TAL, Preston FE. Further evidence that Activated Protein C Resistance affects Protein C coagulant activity assays. Thromb Haemost 2000;83:1712.
  • 63
    Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, Morgan M, Mumford A. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011;96:106671.
  • 64
    Guglielmone HA, Vides MA. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemost 1992;67:469.
  • 65
    Mikami S, Tuddenham EG. Studies on immunological assay of vitamin K dependent factors. II. Comparison of four immunoassay methods with functional activity of protein C in human plasma. Br J Haematol 1986;62:18393.
  • 66
    Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994;86:798803.
  • 67
    Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b binding protein during pregnancy and oral contraception. Br J Haematol 1988;68:43743.
  • 68
    Said JM, Ignjatovic V, Monagle PT, Walker SP, Higgins JR, Brennecke SP. Altered reference ranges for protein C and protein S during early pregnancy: implications for the diagnosis of protein C and protein S deficiency during pregnancy. Thromb Haemost 2010;103:9848.
  • 69
    Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011;86:41821.
  • 70
    Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993;70:106771.
  • 71
    Cooper PC, Hampton KK, Makris M, Abuzenadah A, Paul B, Preston FE. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994;88:2013.
  • 72
    Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005;31:6672.
  • 73
    Bertina RM. Specificity of protein C and protein S assays. La Ricerca in Clinica e in Laboratorio 1990;20:12738.
  • 74
    Bertina RM. Protein S antigen. In: Laboratory Techniques in Thrombosis – A Manual; 2nd revised edition of the ECTA Assay Procedures. Jesperson J, Bertina RM, Haverkate F. (eds). Dordrecht, The Netherlands: Kluwer Academic Publishers; 1999:14152.
  • 75
    Persson KE, Hillarp A, Dahlbäck B. Analytical considerations for free protein S assays in protein S deficiency. Thromb Haemost 2001;86:11447.
  • 76
    Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, Bayliss P, Peake IR, Miller GJ, Preston FE. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000;95:193541.
  • 77
    Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001;113:63641.
  • 78
    Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:77584.